The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
J | Antiinfectives for systemic use | |
2
|
J01 | Antibacterials for systemic use | |
3
|
J01G | Aminoglycoside antibacterials | |
4
|
J01GB | Other aminoglycosides | |
5
|
J01GB01 | Tobramycin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| PAREN | Parenteral | 0.24 g | |
| RESPIR | Respiratory (Inhalation) | 112 g | (powder) |
| RESPIR | Respiratory (Inhalation) | 0.3 g | (solution) |
| Active Ingredient |
|---|
|
Tobramycin is an aminoglycoside antibiotic produced by Streptomyces tenebrarius. It acts primarily by disrupting protein synthesis leading to altered cell membrane permeability, progressive disruption of the cell envelope and eventual cell death. It is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations. |
| Document | Type | Information Source | |
|---|---|---|---|
| TOBI Podhaler Inhalation powder, hard capsule | MPI, EU: SmPC | European Medicines Agency (EU) | |
| TYMBRINEB Nebuliser solution | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.